Abstract

Staccato Loxapine Resubmitted to FDA

Author(s): Peter F. Buckley

In a previous issue of CS we described the profile and some initial registration trial study results for the putative antipsychotic investigational drug Staccato Loxapine. The drug is being developed for use in schizophrenia and mania where there is agitation.

• PDF